Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A <i>post hoc</i> Analysis from the Randomized VERTIS CV Trial.

Cherney, David Z I; Dagogo-Jack, Samuel; Cosentino, Francesco; Pratley, Richard E; Frederich, Robert; Maldonado, Mario; Liu, Chih-Chin; Cannon, Christopher P

Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial.

Cherney, David Z I; Dagogo-Jack, Samuel; Cosentino, Francesco; Pratley, Richard E; Frederich, Robert; Maldonado, Mario; Liu, Chih-Chin; Cannon, Christopher P.

Afiliação

Cherney DZI; Division of Nephrology, University of Toronto, Toronto, Ontario, Canada.
Dagogo-Jack S; Division of Endocrinology, Diabetes & Metabolism & Director, Clinical Research Center, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Cosentino F; Unit of Cardiology, Karolinska Institute & Karolinska University Hospital, Stockholm, Sweden.
Pratley RE; AdventHealth Translational Research Institute, Orlando, Florida, USA.
Frederich R; Pfizer, Inc., Groton, Connecticut, USA.
Maldonado M; MSD Limited, London, UK.
Liu CC; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Cannon CP; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Kidney Int Rep ; 7(8): 1782-1792, 2022 Aug.

Article em En | MEDLINE | ID: mdl-35967112